Max Healthcare Institute Limited has announced the grant of 2,84,520 stock options to eligible employees under its Employee Stock Option Scheme 2022. The company's Nomination and Remuneration Committee (NRC) approved this grant during its meeting held on February 4, 2026.

Grant Details and Structure

The stock option grant is structured in two distinct tranches with different exercise prices and quantities:

Vesting and Exercise Terms

The granted stock options operate under specific vesting and exercise parameters designed to align employee interests with long-term company performance:

The vesting is subject to fulfillment of pre-vesting conditions as determined by the NRC, ensuring that options vest based on performance and tenure criteria.

Regulatory Compliance and Disclosure

The grant has been made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The NRC meeting commenced at 10:15 AM IST and concluded at 10:40 AM IST on February 4, 2026.

Max Healthcare Institute Limited has communicated this development to both major stock exchanges:

• NSE (National Stock Exchange): Symbol MAXHEALTH
• BSE (Bombay Stock Exchange): Scrip Code 543220

The company has also made the disclosure available on its official website at www.maxhealthcare.in , ensuring transparency and accessibility for all stakeholders.

ESOP Scheme Framework

The Max Healthcare Institute Limited Employee Stock Option Scheme 2022 (MHIL ESOP – 2022) serves as the governing framework for these grants. The scheme is administered and implemented by the Nomination and Remuneration Committee, which determines the terms and conditions for option grants, vesting schedules, and exercise parameters.

This employee stock option grant represents Max Healthcare's commitment to employee retention and motivation through equity participation, allowing eligible employees to benefit from the company's long-term growth and performance.

Max Healthcare Institute Limited has announced the initiation of voluntary liquidation proceedings for its wholly-owned subsidiary MHC Global Healthcare (Nigeria) Limited under the applicable laws of Nigeria. The company disclosed this development on January 29, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Impact Assessment

The subsidiary's contribution to the group's consolidated financials as of March 31, 2025, demonstrates minimal impact on the parent company's overall performance:

The negative networth of ₹70,89,724 represents a negligible percentage of the consolidated financials, reinforcing the subsidiary's non-material status.

Corporate Structure and Business Impact

Max Healthcare Institute Limited has emphasized that MHC Global Healthcare (Nigeria) Limited is not classified as a material subsidiary of the company. The management has assured stakeholders that the voluntary liquidation process will neither affect any existing business operations nor create a material impact on the company's consolidated financial statements.

Liquidation Process and Timeline

MHC Nigeria has initiated the process for filing the requisite application with the Corporate Affairs Commission and other relevant authorities in Nigeria for voluntary liquidation. The company has committed to providing further updates to the stock exchanges upon completion of the liquidation formalities.

Regulatory Compliance

The disclosure was made in accordance with SEBI regulations, with the company receiving the intimation on January 29, 2026, at 5:23 PM IST. The announcement has been communicated to both the National Stock Exchange of India Limited and BSE Limited, and the disclosure is also hosted on the company's official website at www.maxhealthcare.in .

This strategic decision reflects Max Healthcare's focus on optimizing its corporate structure by divesting non-performing international subsidiaries while maintaining its core healthcare operations in India.